Stockreport

Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF This compares to the stock's 9.5% gain over the past four weeks. Travere Therapeutics' stock surged after the FDA approved Filspari for a second rare kidney disease, m [Read more]